Medical Device

1000 usd to cad

Contakt World Launches Sales Representative Program to Continue to Grow Revenue for Its Cash Flow Positive HealthCheck Screening Tool and Vaccine Passport Solution

Independent sales representatives provide scalable technology sales opportunity for health screening and vaccine passports to Contakt World and its portfolio companies

  • HealthCheck's existing 1,000+ customer sites were acquired through sales efforts of one part-time independent sales representative and two founders leading to $1.55M CAD revenue and $555K CAD net profit for the twelve-months ended July 31, 20211
  • In addition to plans to bolster its revenue opportunities with vaccine passports and validation, Contakt World just launched a program to aggressively add independent sales representatives to scale sales within employer establishments, K-12 schools and event venues in the US
  • Contakt World's advertisements and initial screening process to add independent sales representatives for health screening, vaccine passports, and future solutions yielded dozens of qualified applicants in less than two weeks
  • Independent sales representatives are expected to grow customer base and increase revenue for HealthCheck and future solutions like vaccine passports on a commission-only basis

Contakt World Technologies Corp. (CSE: HELP) (OTC: TLOOF) (FSE: B2I0) (the "Company" or "Contakt World"), a SaaS company committed to improving health equity and access to healthcare while solving sector specific business challenges like symptom screening and vaccine passports, today announced it will create a network of independent sales representatives to scale sales for the recently acquired HealthCheck app, vaccine passports, and future acquisitions or partnering products.

Contakt World's processes for independent sales representatives are being designed for efficient onboarding, CRM to track leads and sales, recurring trainings, and lead generation to support independent sales representatives. Independent sales representatives will be paid a commission of 10% on their collected sales from health screening, vaccine passports, and future products.

"A single independent sales representative working on a commission-basis led to hundreds of commercial users for HealthCheck and 12-month trailing revenues of $1.55M CAD1, as at July 31, 2021, before we acquired the company," stated Justin Beck, Chief Visionary Officer for Contakt World. "HealthCheck is an attractive solution for organizations of all shapes and sizes, where liabilities relating to COVID-19, vaccine passports, symptom screening, and safety are reduced through our SaaS solutions. More independent representatives to sell our solutions means more sales opportunities for Contakt World." Contakt has initiated the onboarding of several sales representatives with the goal of contracting a team of 15-20 people in the next 30-60 days distributed across multiple states in the United States.

In addition to its efforts to add vaccine credentials and vaccine validation to the HealthCheck screening tool, Contakt World is negotiating with several partner technologies to bolster its SaaS portfolio for customers in a number of health-related fields. Symptom screening, vaccine passports, vaccine validation, and other methods to improve population safety and reduce liability are becoming key to everyday business, travel, and social life.

Other Recent Related News from Contakt World:

Contakt World to Offer Vaccine Passport and Verification Platform to Employers, Events and Organizations, Including Customers of Recently Acquired HealthCheck App

Contakt World Announces Acquisition of HealthCheck, a SaaS Health Screening App for Students, Customers, Employees, and Visitors

Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

To Learn More:

To receive investor updates from Contakt World Technologies Corp. including its efforts in the field of vaccine passports, click here.

If you are an organization seeking daily health screening and future vaccine passports, schedule a demo of HealthCheck by clicking here.

About Contakt World

Contakt World's mission is to develop or acquire and deliver software (SaaS) that improves access to, efficiencies within, and quality of healthcare in all its forms. Contakt World envisions a world where everyone can achieve their full health potential, and no one is disadvantaged from achieving this potential because of social position or other circumstances. Contakt World's portfolio presently includes the award-winning software platform, Smart Health RM, and HealthCheck by Stratum which is used in over 1,000 locations. For more information, please visit https://contakt.world/.

Sign up for investor updates from Contakt World including updates in the field of vaccine passports by visiting https://contakt.world/help.

Contakt World Contact
Zayn Kalyan
Interim CEO and Director
Direct: 778-938-3367

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Forward-Looking Statements Disclaimer

This press release contains "forward-looking information" within the meaning of applicable securities laws ("forward-looking statements"). Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "projects", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements, including statements respecting: Healthcheck's integration into Contakt World's offerings, business plan and growth strategy; Healthchecks's prospects as a platform and service; Contakt World's ability to scale and sell HealthCheck, including through its new sales representative program; Contakt Worlds's work to bolster its SaaS portfolio; Contakt World's ability to deploy a successful vaccine passport; and Contakt World's ability to leverage Healthcheck going forward. Although forward-looking statements contained in this press release are based upon what management of Contakt World believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements may also be affected by risks and uncertainties in the business of Contakt World, including those described in the Company's public filings available on www.SEDAR.com. Contakt World undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

____________________

1 Unaudited, based on management prepared financial information for the 12-months ending July 31,2021 using 1 USD to 1.26 CAD exchange rate on August 31, 2021.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/95097

News Provided by Newsfile via QuoteMedia

Alkaline Fuel Cell Power Corp. Announces the Closing of New Credit Facilities and Update on the Previously Announced Private Placement

Alkaline Fuel Cell Power Corp. Announces the Closing of New Credit Facilities and Update on the Previously Announced Private Placement

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) (" PWWR " or the " Company "), a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce that it has entered into a credit agreement (the " Credit Agreement ") with Juno Financial Group Corporation (" Juno ") for a fixed rate loan to the Company for a gross amount of approximately CAD $800,000 (the " Loan "). The entire Loan amount will be provided to the Company immediately and is expected to be used for general corporate purposes.

"We are pleased to be working with Juno with their cleantech experience, and we saw the loan as a more immediate opportunity to fund our current needs, thus postponing our private placement," stated Frank Carnevale, Chief Executive Officer."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health Corporate Update - Earnings Advisory 2022 and 2023 Objectives

Avricore Health Corporate Update - Earnings Advisory 2022 and 2023 Objectives

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is entering the second year of a multi-year growth plan to bring HealthTab, its turnkey solution for point of care testing and data management, to more pharmacies across Canada and the world. As part of this effort the Company is pleased to provide insight into the successes of last year and lay out updates and objectives on further progress.

"Last year we set out bold targets and today we can demonstrate we've been able to achieve them," said Hector Bremner, CEO of Avricore Health Inc. "There's no doubt that we are poised for significant growth in 2023 and beyond."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
E-Power Resources Announces Director Change

E-Power Resources Announces Director Change

E-Power Resources Inc (CSE: EPR) ("E-Power" or the "Company") announces that Ms. Anna Oxenstierna has resigned from the board of directors of the Company, and the board has accepted her resignation. The Company thanks Ms. Oxenstierna for her contributions and wishes her well on her future endeavors.

The Company is currently in discussions with suitable candidates to replace Ms. Oxenstierna. An announcement will be made in due course.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Alkaline Fuel Cell Power Corp. Announces AGM Results

Alkaline Fuel Cell Power Corp. Announces AGM Results

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP" or the "Company") a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, is pleased to announce the results of voting at its annual general meeting (" AGM ") of shareholders which was held on January 25, 2023 in person in Vancouver, British Columbia and by conference call (the " Meeting "). There were 19 shareholders represented in person or by proxy at the Meeting holding 2,423,369 common shares, representing 1.39% of the Company's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting is set out below:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Alkaline Fuel Cell Power Announces Resignation of Director

Alkaline Fuel Cell Power Announces Resignation of Director

Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP" or the "Company") a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech, announces the resignation of Joel Dumaresq as director, effective January 12, 2023. Mr. Dumaresq will remain as the Chief Financial Officer of the Company while the Company seeks a suitable replacement.

ABOUT Alkaline Fuel Cell Power CORP.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BriaCell CEO Letter to Shareholders

BriaCell CEO Letter to Shareholders

  • Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization.
  • Successful completion of the pivotal study could be followed by a Biologics License Application submission and commercialization.
  • Pivotal study's primary endpoint to be linked to survival improvement.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today issues a letter to shareholders from Dr. William V. Williams, BriaCell's President and CEO.

Dear BriaCell Shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×